-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM)
-
-
-
-
-
-
-
Rhythm Pharmaceuticals (RYTM) PT Lowered to $141 at Goldman Sachs
-
-
-
-
-
-
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $157 at Goldman Sachs
-
-
-
-
-
-
-
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology
-
-
-
-
-
-
-
Rhythm Pharmaceuticals Presents Initial Data from Long-term Extension Trial Evaluating Setmelanotide in Rare Genetic Diseases of Obesity at ENDO 2022
-
-
-
-
-
-
-
Rhythm Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Update
-
-
-
-
-
-
-
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
-
15,434 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

